LIVZON PHARMAC. GRP H YC1 (LP6) — Capital Reinvestment Ratio
LIVZON PHARMAC. GRP H YC1 (LP6) has a Capital Reinvestment Ratio of 0.18x as of December 2025, meaning it reinvests 0% of its operating cash flow (€3.15 Billion) in capital expenditures (€574.14 Million). See LIVZON PHARMAC. GRP H YC1 balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
LIVZON PHARMAC. GRP H YC1 Capital Reinvestment Ratio (2021–2025)
This chart tracks LIVZON PHARMAC. GRP H YC1's Capital Reinvestment Ratio across 5 annual periods. Check LP6 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for LIVZON PHARMAC. GRP H YC1 (2021–2025)
Year-by-year Capital Reinvestment Ratio for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. For live market cap and broader valuation context, see LP6 company net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | €3.15 Billion | €574.14 Million | ▼ -4.6% |
| 2024 | 0.19x | €2.98 Billion | €570.16 Million | ▼ -24.2% |
| 2023 | 0.25x | €3.25 Billion | €820.45 Million | ▼ -25.5% |
| 2022 | 0.34x | €2.77 Billion | €940.15 Million | ▼ -50.7% |
| 2021 | 0.69x | €1.90 Billion | €1.31 Billion | — |